
Candel Therapeutics, Inc.: updates and filings
Price
$5.04
November 20, 2026Market cap $395M
What Ploutos Investor adds for Candel Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 40% since Nov 12, 2026, when the 10-Q these figures come from was filed ($8.39 then, $5.04 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Other material eventsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Sep 10, 2026Officer or director change, Regulation FD disclosureForm8-K
- Sep 9, 2026Regulation FD disclosureForm8-K
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jul 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 24, 2026Shareholder voteForm8-K
- Jun 16, 2026Officer or director changeForm8-K
- May 15, 2026Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Apr 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 18, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 12, 2026Shares registered for employeesFormS-8
- Mar 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 12, 2026Results of operationsForm8-K
- Feb 23, 2026Material agreement entered, other material eventsForm8-K
- Feb 19, 2026Material agreement entered, results of operations, Regulation FD disclosure, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 8-K | Other material events | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Sep 10, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Sep 9, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jul 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 24, 2026 | 8-K | Shareholder vote | Document |
| Jun 16, 2026 | 8-K | Officer or director change | Document |
| May 15, 2026 | 8-K | Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 18, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 12, 2026 | S-8 | Shares registered for employees | Document |
| Mar 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 12, 2026 | 8-K | Results of operations | Document |
| Feb 23, 2026 | 8-K | Material agreement entered, other material events | Document |
| Feb 19, 2026 | 8-K | Material agreement entered, results of operations, Regulation FD disclosure, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 16, 2021.
The full analysis
What do Candel Therapeutics's filings show?
The filings are where every one of Candel Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.